Aptorum Group Limited (NASDAQ:APM) Short Interest Update

Aptorum Group Limited (NASDAQ:APM) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 227,700 shares, a drop of 26.8% from the August 31st total of 311,200 shares. Approximately 5.3% of the company’s shares are sold short. Based on an average daily trading volume, of 9,700,000 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily trading volume, of 9,700,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 5.3% of the company’s shares are sold short.

Aptorum Group Price Performance

NASDAQ APM opened at $2.32 on Tuesday. The firm has a 50 day simple moving average of $1.83 and a 200-day simple moving average of $1.30. Aptorum Group has a one year low of $0.46 and a one year high of $7.49.

Analyst Upgrades and Downgrades

APM has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Aptorum Group in a report on Saturday, September 27th. Wall Street Zen upgraded Aptorum Group to a “sell” rating in a research note on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.